CHO Cell Expression System for High-Yield Biopharmaceuticals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current expression systems for producing biopharmaceuticals face challenges in achieving high yield and purity, with issues of adventitious contamination and regulatory approval complexities, particularly for biosimilars, due to the need for compatibility with host cell machinery and stringent quality control requirements.
Innovation Solution
The development of a novel expression system using Chinese Hamster Ovary (CHO) cells that constitutively express human growth hormone (hGH), combined with a dihydrofolate reductase (DHFR) deficiency and prokaryotic selectable markers, allows for the production of recombinant proteins like Infliximab and Erythropoietin in a cost-effective, serum-free medium, with detailed manipulation records to ensure regulatory compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional expression systems are used for producing biopharmaceuticals, then production can be achieved, but yield and purity are limited with risks of adventitious contamination
Solution Approach 1:
The patent segments the expression system into distinct functional components: a defined serum-free medium composition, specific CHO cell line characteristics, and controlled cultivation parameters. This segmentation allows each component to be optimized independently for both high yield and high purity, eliminating the contamination risks associated with undefined serum components while maintaining productivity.
Solution Approach 2:
The patent changes critical parameters by transitioning from serum-containing to serum-free defined medium, optimizing cell line characteristics (CHO cell line with specific properties), and adjusting cultivation conditions. These parameter changes simultaneously improve purity (by eliminating serum contaminants) and maintain/yield productivity (through optimized defined medium composition and cell line selection).
2Reliability
If stringent quality control and detailed manipulation records are implemented, then regulatory compliance and product safety are improved, but process complexity and time requirements increase
Solution Approach 1:
The patent applies preliminary action by establishing a well-defined serum-free medium composition and characterized CHO cell line before production begins. The defined medium recipe and cell line properties are predetermined and documented, which simplifies subsequent quality control and regulatory documentation by eliminating the need to characterize undefined serum components during the approval process.
Solution Approach 2:
The system is designed to be self-documented through the use of defined parameters and characterized cell lines. The defined medium composition and cell line properties inherently provide the documentation needed for regulatory compliance, reducing the burden of external quality control measures and simplifying the overall process complexity.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
An expression system for expressing a protein comprising: a eukaryotic host cell carrying a dihydrofolate reductase (DHFR) deficiency; and an expression vector, the expression vector encoding the human growth hormone gene; a expression vector, the expression vector comprising: a eukaryotic selectable marker including a minimal SV 40 early promoter driving expression of a sequence encoding dihydrofolate reductase for complementing the DHFR deficiency in the host cell; a prokaryotic selectable marker conveying Ampicillin resistance to a prokaryotic host cell; a prokaryotic Origin of Replication; a plurality of multiple cloning sites (MCS); and at least one protein expression module comprising: a Simian Vacuolating Virus 40 (SV40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit β-globin intron sequence being separable from a SV40 p A sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom.